NEWS RELEASES
19 November 2008
PharmaMar presented the Award "Supporting A Cure In Our Time" of the Sarcoma Foundation of America (SFA) for its commitment with research in soft tissue sarcoma
17 November 2008
YONDELIS ® (trabectedin) DATA PRESENTED AT THE 11th CONGRESS OF THE PORTUGUESE SOCIETY OF ONCOLOGY
Funchal, November 17th, 2008: An overview of YONDELIS® (trabectedin), a new therapy for the treatment of soft tissue sarcoma, a rare type of cancer with a prevalence of one percent of all tumours in adults, was presented in the 11th Congress of the Portuguese Society of Oncology on November 17.
24 October 2008
The FDA approves the Production Process Strategy of Aplidin® proposed by PharmaMar
Madrid, October 24th, 2008: The Food and Drug Administration (FDA) has accepted the proposal made by PharmaMar, of the Zeltia Group for the production process of Aplidin®, a new marine-derived anti-tumor agent, in clinical development for the treatment of hematological and solid tumors.
23 October 2008
PharmaMar presents new data of Zalypsis® and Irvalec® in pediatric, solid tumours and lymphoma at the 20th AACR-NCI-EORTC Symposium
Geneva, 23 October, 2008: PharmaMar, a biotechnology company of Zeltia Group, has presented new data on two antitumoral compounds of marine origin, Zalypsis® and Irvalec®, in Phase I trials in clinical development and in vitro studies and with animal models.
23 October 2008
PharmaMar, honored by Elsevier Galien for “Excellence in R & D and innovation in Biotechnology”
Madrid, October 23th, 2008: PharmaMar, a biotechnology company of Zeltia Group, was honored yesterday by Elsevier Galien for “Excellence in R & D and innovation in Biotechnology”, one of the prizes that Elsevier Publishing Group awards in recognition of excellence and commitment of public and private institutions for the benefit of research and health.
15 September 2008
PHARMAMAR PIVOTAL STUDY OF YONDELIS® IN OVARIAN CANCER SHOWS A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL PROLONGATION IN PROGRESSION FREE SURVIVAL
04 September 2008
THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY SELECTS YONDELIS® PIVOTAL STUDY IN OVARIAN CANCER FOR THE PRESIDENTIAL SYMPOSIUM
Madrid, 4th September 2008: The organising committee of the 33rd congress of European Society for Medical Oncology (ESMO) has selected the Phase III pivotal study of Yondelis in ovarian cancer for presentation during the presidential symposium, to be held next 15th of September.
07 August 2008
Public Announcement to the Spain's National Securities Market Commission
Madrid, 7 August 2008
Pursuant to Article 82 of the Spanish Stock Market Law, hereby we communicate the following SIGNIFICANT EVENT:
09 July 2008
In Japan, PharmaMar will have a new partner
Madrid, July 9th 2008: PharmaMar has announced that from now on the development and, where appropriate, the marketing of Yondelis in Japan will be carried out by PharmaMar – and to this end PharmaMar may collaborate with other licensees.
12 June 2008
Realising the Promise of Personalized Medicine in the Treatment of Cancer
Madrid, June 12th 2008: The symposium on Sarcomas “Paradigm for Personalized Medicine and Targeted Therapies: New Directions and Innovative Approaches to Diagnosis and Treatments” was held last June 1 in Chicago, coinciding with the Annual congress of the American Society of Clinical Oncology (ASCO). The forum, organized by the Sarcoma Foundation of America (SFA) and the Center for Biomedical Continuing Education (CBCE), was led by oncologist George D. Demetri, director of the Ludwig Center at Dana-Farber/Harvard Cancer Center. The event was attended by nearly 200 professionals among pathologists, oncologists and molecular biologists.
09 June 2008
PHARMAMAR PRESENTS NEW DATA OF YONDELIS®, IRVALEC® (PM02734) AND APLIDIN® IN ASCO
Madrid, June 9th 2008: PharmaMar, a biopharmaceutical company of the Zeltia Group (ZEL) specialized in the development and commercialization of marine derived drugs against cancer, has presented new data on three of its compounds in development: Yondelis®, PM02734 (Irvalec®) and Aplidin®. Four relevant studies were presented at the 20087Annual Meeting of the American Society of Clinical Oncology (ASCO) which took place in Chicago, from May 30th- June 3rd.
08 May 2008
THE REGULATORY BODY OF SOUTH KOREA HAS APPROVED THE COMMERCIALISATION OF YONDELIS® FOR THE TREATMENT OF SOFT TISSUE SARCOMA
• Johnson & Johnson through its subsidiary in South Korea has received the approval of Yondelis® for the treatment of advanced soft tissue sarcoma in adults.
• South Korea is the first country outside the EU where Yondelis® has been approved.
• Yondelis® has been designated orphan drug for the treatment of soft tissue sarcomas and ovarian cancer in the European Union, United States and Switzerland.
• PharmaMar will market Yondelis® in Europe (including Eastern Europe) while J&J´s Ortho Biotech Products, L.P., will market it in the U.S., and J&J´s Janssen-Cilag will market it in the rest of the world.
• According to the licensing agreement with Johnson & Johnson, PharmaMar will receive royalties on the sales of Yondelis® in South Korea.
• South Korea has a population of 49 million people. The size of its pharmaceutical market is similar to the Spanish.
• Soft tissue sarcomas (STS) have an incidence of approximately 3/100,000 new cases per year, representing 2% of the overall mortality from cancer.
21 April 2008
PHARMAMAR PRESENTED AT THE AACR NEW MODELS OF RATIONAL DEVELOPMENT OF MARINE COMPOUNDS FOR CANCER TREATMENT
• Aplidin® shows an activity profile against tumour stem cells far superior than that of other cytotoxic drugs.
• PM02734, in contrast to cisplatin and other conventional drugs, inhibits AKT signalling pathway (protein kinase B), key enzyme involved in cell proliferation, angiogenesis (formation of blood vessels) and apoptosis (programmed cell death) pathways.
• The results obtained with both compounds form the basis for the implementation of rational development models with clinical potential in the treatment of solid tumours and haematological malignancies.
02 April 2008
YONDELIS® HAS BEEN GRANTED ORPHAN DRUG STATUS BY THE SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SWISSMEDIC) FOR THE TREATMENT OF SOFT TISSUE SARCOMA AND OVARIAN CANCER
• A Marketing Authorization Application for Yondelis in Ovarian Cancer is expected to be submitted to the EMEA during 2008.
• Ovarian cancer represents 4% of all female cancers and it is the 5th cause of death from cancer in women (American Cancer Society [ACS], Cancer Reference Information, 2005)
• Yondelis is being commercialized in the European Union for the treatment of advanced soft tissue sarcomas in adults
27 March 2008
PHARMAMAR RECEIVES GREEN LIGHT FROM CHMP FOR THE PROTOCOL FOR A PIVOTAL TRIAL OF YONDELIS® AS FIRST-LINE TREATMENT OF PATIENTS WITH SOFT-TISSUE SARCOMA associated with translocations
Madrid, March 27, 2008: The EMEA's Committee for Medicinal Products for Human Use (CHMP) has accepted PharmaMar's proposal for an international randomised multi-centre pivotal Phase III trial of Yondelis as first-line treatment of patients with soft tissue sarcoma associated with specific chromosomal translocations.
17 March 2008
PHARMAMAR INITIATES A PHASE II STUDY OF YONDELIS® IN CHILDREN WITH RECURRENT SOFT TISSUE SARCOMAS
Yondelis is being commercialized in the European Union for the treatment of advanced soft tissue sarcoma in adults.
[...]
